BTMD catalyst calendar

biote Corp.

Upcoming catalysts
2
Cash runway
Cash generating
Cash & investments
$11M
Phase 3 programs
7

biote Corp. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Medicinal Chemicals & Botanical Products.

The next scheduled catalyst is Next quarterly earnings (projected) on November 4, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

biote Corp. generates cash from operations, so a burn-based runway figure does not apply.

Across 23 concluded trials, 74% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 4, 2026 est. Next quarterly earnings (projected) Earnings —
July 31, 2028 Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) Trial Milestone Phase 3

Track BTMD alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open BTMD in the tracker

Recent history

DateEventTypePhase
August 5, 2026 Quarterly results filed (8-K) Earnings —
June 17, 2026 8-K/A filed: Leadership change Corporate —
June 2, 2026 8-K filed: Leadership change, Reg FD disclosure Corporate —
May 6, 2026 Quarterly results filed (8-K) Earnings —
April 3, 2026 8-K filed: Reg FD disclosure Filing —
March 11, 2026 Quarterly results filed (8-K) Earnings —
January 26, 2026 8-K filed: Other event Filing —
November 5, 2025 Quarterly results filed (8-K) Earnings —
August 6, 2025 Quarterly results filed (8-K) Earnings —
June 9, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
June 5, 2025 8-K filed: Leadership change Corporate —
May 7, 2025 Quarterly results filed (8-K) Earnings —
May 5, 2025 Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia Trial Milestone Phase 3
April 24, 2025 8-K filed: Leadership change Corporate —
November 19, 2023 Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion) Trial Milestone Phase 3
September 25, 2023 Adjusted Fibrinogen Replacement Strategy Trial Milestone Phase 3
May 10, 2022 Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19 Trial Milestone Phase 2
June 29, 2021 Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19 Trial Milestone Phase 2
May 18, 2020 Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency Trial Milestone Phase 3
April 1, 2020 Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID Trial Milestone Phase 3
December 15, 2018 This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP) Trial Milestone Phase 3
November 8, 2018 Study of the Safety of USB005 in Healthy Volunteers Trial Milestone Phase 1
October 30, 2018 BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Trial Milestone Phase 1/Phase 2
October 25, 2017 Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.